A Tale Of Two Drugs: Atrial Fibrillation Reviews Draw Focus On RiskMAPS
Executive Summary
At the recent Cardiovascular and Renal Drugs Advisory Committee hearing for two atrial fibrillation drugs, the panel recommended approval of Astellas/Cardiome's Kynapid (vernakalant) without fully knowing its quantified risks, but shot down Solvay's Pulzium (tedisamil), which came with an extensive risk management plan and safety and efficacy data the committee touted as transparent and thorough
You may also be interested in...
Sanofi-Aventis Pares Pipeline, Ditches Antidepressant Amibegron
In light of clinical setbacks and a broader overhaul, Sanofi-Aventis has ended some once-promising advanced development programs, while the fates of others hang in the balance, pending study results and strategic reviews
The Role Of RiskMAPs: Fentora Shows Shift From Post-Market To Pre-Market
Cephalon needs to improve the risk management plan for its breakthrough cancer pain drug Fentora regardless of whether it expands use to non-cancer pain patients, according to FDA and a joint Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committee
The Role Of RiskMAPs: Fentora Shows Shift From Post-Market To Pre-Market
Cephalon needs to improve the risk management plan for its breakthrough cancer pain drug Fentora regardless of whether it expands use to non-cancer pain patients, according to FDA and a joint Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committee